GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (OTCPK:TKPHF) » Definitions » Retained Earnings

TKPHF (Takeda Pharmaceutical Co) Retained Earnings : $10,015 Mil (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Takeda Pharmaceutical Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Takeda Pharmaceutical Co's retained earnings for the quarter that ended in Sep. 2024 was $10,015 Mil.

Takeda Pharmaceutical Co's quarterly retained earnings declined from Mar. 2024 ($9,286 Mil) to Jun. 2024 ($8,477 Mil) but then increased from Jun. 2024 ($8,477 Mil) to Sep. 2024 ($10,015 Mil).

Takeda Pharmaceutical Co's annual retained earnings declined from Mar. 2022 ($12,479 Mil) to Mar. 2023 ($11,530 Mil) and declined from Mar. 2023 ($11,530 Mil) to Mar. 2024 ($9,286 Mil).


Takeda Pharmaceutical Co Retained Earnings Historical Data

The historical data trend for Takeda Pharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Retained Earnings Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,724.12 13,890.70 12,478.90 11,529.98 9,285.92

Takeda Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,780.64 9,701.51 9,285.92 8,477.08 10,015.00

Takeda Pharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Takeda Pharmaceutical Co  (OTCPK:TKPHF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Takeda Pharmaceutical Co Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.